cohorts 1-4:

1. Provided evidence of a signed consent

2. Age ≥ 18 and ≤ 75 years

3. Healthy overweight/obese adult men and women with body mass index ≥ 27 and ≤ 40 kg/m2

4. No nicotine use

5. Have a suitable venous access for blood sampling

Inclusion Criteria cohort 5:

1. Men and women with T2DM of ≥6 months duration

2. Age ≥ 18 and ≤ 75 years

3. BMI ≥ 27 and ≤ 40 kg/m2

4. Treated with stable doses of ≥500 mg of metformin with a duration ≥6 months and at stable doses for ≥2 months with a screening HbA1c ≥7.0% and ≤10.5%.

1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or major surgery within the major 3 months

2. A sitting BP after resting for 5 minutes > 160mm Hg systolic or > 100 mm Hg diastolic or an apical pulse rate <50 or >100 beats per minute.

3. Evidence of abnormality on the screening visit ECG, or a history of known arrhythmia or prolonged QTcF pr prolonged QRS interval

4. Liver function test results elevated > 2.0-fold above the ULN for gamma glutamyl transferase, alkaline phosphatase, aspartate aminotransferase or alanine aminotransferase. Bilirubin above the ULN

5. Estimated glomerular filtration rate < 60mL/min/1.73 m2 body surface area

6. Known hypersensitivity to any of the study drug ingredients

7. Any other condition or prior therapy that would make the participant unsuitable for this study